Ordinary Rebalance | Solactive Pharma Breakthrough Value Index | 19th September 2022
In the ordinary rebalancing the following index composition will be implemented effective open 19.09.2022:
ABBVIE INC |
ALNYLAM PHARMACEUTICALS INC |
AMICUS THERAPEUTICS INC |
BASILEA PHARMACEUTICA LTD. |
BEIGENE LTD-ADR |
BIOGEN INC |
BIOMARIN PHARMACEUTICAL INC |
BRISTOL-MYERS SQUIBB CO |
CHUGAI PHARMACEUTICAL CO LTD ORD |
CLINUVEL PHARMACEUTICALS LTD |
CSL LTD ORD |
EMERGENT BIOSOLUTIONS INC |
GRIFOLS SA CLASS A |
HORIZON THERAPEUTICS PLC |
INCYTE CORP |
IPSEN SA |
JAZZ PHARMACEUTICALS PLC |
NIPPON SHINYAKU CO LTD |
NOVARTIS AG-ADR |
PHARMA MAR SA |
PTC THERAPEUTICS INC |
ROCHE HOLDING AG |
SANOFI SA |
SEAGEN INC |
SINO BIOPHARMACEUTICAL LTD ORD |
SUPERNUS PHARMACEUTICALS INC |
SWEDISH ORPHAN BIOVITRUM AB |
TRAVERE THERAPEUTICS INC |
ULTRAGENYX PHARMACEUTICAL INC |
UNITED THERAPEUTICS CORP |
VERTEX PHARMACEUTICALS INC |
XENCOR INC |